Amgen said Monday it would purchase Horizon Pharmaceuticals for $27.8 billion, marking the latest bet by a large pharmaceutical company on the lucrative market for treating a rare disease.
The deal is the largest pharma merger announced this year, and it represents the most that Amgen has spent on an acquisition since its $16 billion purchase of Immunex in 2001. However, Amgen is now a much larger company, with annual revenues of $26 billion and a market capitalization of almost $150 billion.
“The acquisition of Horizon is a compelling opportunity for Amgen and one that is consistent with our strategy of delivering long-term growth by providing innovative medicines that address the needs of patients who suffer from serious diseases,” said Robert Bradway, Amgen’s chairman and CEO, in a statement. He said the acquisition is expected to be accretive in 2024.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect